ClinicalTrials.Veeva

Menu
C

Cardiovascular Associates Research, LLC | Covington, LA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

sodium
Triglycerides
Pemafibrate
CER-001
TQJ230
Finerenone
BAY 2433334
Inclisiran
Apixaban

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 9 total trials

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Active, not recruiting
Primary Prevention of Atherosclerotic Cardiovascular Disease
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Drug: Placebo in 1.5ml

Study CTQJ230A12303 is a randomized, double-blind placebo-controlled, Phase IIIb study to evaluate the efficacy, safety and tolerability of pelacarse...

Enrolling
Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease
Drug: TQJ230
Drug: Placebo

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Inclisiran sodium 300 mg

Trial sponsors

Bayer logo
Novartis logo
C
Kowa logo
S

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems